November 23, 2022
It is a great pleasure to announce that EXCITE International has become a member of the FDA's Early Payor Feedback Program (EPFP) set up by the Center for Devices and Radiological Health (CDRH).
Learn More here
EXCITE International Early Technology Review: Unprecedented Opportunity to Engage with the Largest U.S. Payers and Renowned Experts
October 7, 2022
Technologies that improve patient outcomes and deliver service efficiencies deserve to be well-integrated into healthcare systems. Unfortunately, the path to adoption is complex, and many companies get bogged down due to a poor understanding of what payers and health professionals require.
In response, the not-for-profit EXCITE International has developed a collaborative process for Early Technology Review (ETR) that includes direct engagement with large payers and accomplished clinical experts.
Learn More here
It is a great pleasure to announce that EXCITE International has become a member of the FDA’s Early Payor Feedback Program (EPFP) set up by the Center for Devices and Radiological Health (CDRH). This is a voluntary opportunity for medical device sponsors to obtain payor input on clinical trial design or other plans for gathering clinical evidence needed to support positive coverage decisions.
With this EXCITE partnership, Izotropic will engage with EXCITE’s global network to align the device, clinical trial design, and regulatory strategy with potential payor groups, methodologists, and expert end-users.
EXCITE International is a not for profit collaborative focused on fixing unacceptable market adoption problems for innovative nondrug medical technologies.
EXCITE International wishes to announce that Naomi Aronson will be stepping down as Chair of the Payers’ Advisory Committee (PAC) effective August 31st. We are, at the same time pleased to announce that Jo Carol Hiatt, Chair of the Inter-Regional New Technology Committee at Kaiser Permanente has agreed to succeed Naomi as Chair.
EXCITE International's Payers' Advisory Committee welcomes two new members. Robert Garnett is President, Amerigroup Tennessee, part of the Medicaid Central Region and Government Business Division at Anthem, Inc. where he is responsible for the strategic, fiscal, regulatory, and operational leadership of the health plan. Stig A. Slørdahl MD, is CEO of The Central Norway Regional Health Authority. He was dean of the Faculty of Medicine at the Norwegian University of Science and Technology (NTN...
EXCITE International is pleased to announce the appointment of Jeffrey J. Popma, MD as chair of its Scientific Collaboration. This appointment follows the retirement of Dr Bryan Luce who has been chair since the inception of EXCITE International in 2016.
EXCITE International held a Health Technology Global Summit in Washington, DC in March 2019. The event was well attended and very well received. To learn more about the Summit, Read more
EXCITE International is pleased to share with you recent news highlighting the ongoing expansion and partnership development taking place in our organization. Get acquainted with our new executive board members, Sir Bruce Keogh and Carl Christian Gilhuus-Moe in addition to latest developments in our offerings, invaluable partnerships, the launch of new board committees and recent meetings and presentations.
EXCITE International’s approach to accelerating health technology innovation generated immediate interest at the 9th Annual Medical Technology Executive Forum hosted by the Medical Device Manufacturers Association (MDMA) in Palo Alto, California on September 29, 2016.
EXCITE International (Excellence in Clinical Innovation & Technology Evaluation) convened high-level health care leaders from around the world at an inaugural multijurisdictional Summit on June 2-3, 2016 in Toronto.
The inaugural meeting of the Executive Board for EXCITE International occurred in Toronto on Feb 23, 2016.
Incorporated in March 2016, EXCITE International represents a major positive disruption in the application of evidence to the evaluation of technology and has the potential to be a first-of-its kind global engine for medical technology innovation.